Resonance Specialities Ltd
₹ 78.4
0.01%
24 Apr
10:21 a.m.
About
Incorporated in 1989, Resonance Specialties Ltd manufactures Pyridine, Picoline, Cynopyridine and derivatives of the same[1]
Key Points
- Market Cap ₹ 90.5 Cr.
- Current Price ₹ 78.4
- High / Low ₹ 129 / 65.0
- Stock P/E 19.9
- Book Value ₹ 51.9
- Dividend Yield 0.00 %
- ROCE 7.26 %
- ROE 5.23 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- The company has delivered a poor sales growth of 5.78% over past five years.
- Company has a low return on equity of 12.9% over last 3 years.
- Debtor days have increased from 68.6 to 88.7 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
39.52 | 45.30 | 37.84 | 38.63 | 33.91 | 35.71 | 41.40 | 56.14 | 70.29 | 75.76 | 57.98 | 54.82 | 69.96 | |
37.36 | 42.19 | 36.59 | 35.62 | 31.89 | 35.06 | 36.51 | 48.39 | 56.04 | 59.01 | 51.15 | 49.94 | 62.56 | |
Operating Profit | 2.16 | 3.11 | 1.25 | 3.01 | 2.02 | 0.65 | 4.89 | 7.75 | 14.25 | 16.75 | 6.83 | 4.88 | 7.40 |
OPM % | 5.47% | 6.87% | 3.30% | 7.79% | 5.96% | 1.82% | 11.81% | 13.80% | 20.27% | 22.11% | 11.78% | 8.90% | 10.58% |
0.38 | -0.38 | 1.86 | 0.26 | 0.82 | 1.08 | 1.31 | 0.44 | 1.59 | 1.36 | 1.61 | 0.93 | 0.40 | |
Interest | 0.76 | 0.59 | 0.58 | 0.52 | 0.39 | 0.55 | 0.54 | 0.35 | 0.29 | 0.07 | 0.11 | 0.39 | 0.43 |
Depreciation | 1.15 | 1.10 | 1.16 | 1.12 | 1.06 | 1.15 | 0.91 | 0.92 | 0.98 | 1.75 | 1.48 | 1.46 | 1.82 |
Profit before tax | 0.63 | 1.04 | 1.37 | 1.63 | 1.39 | 0.03 | 4.75 | 6.92 | 14.57 | 16.29 | 6.85 | 3.96 | 5.55 |
Tax % | 25.40% | 0.96% | 7.30% | 27.61% | 25.90% | 2,700.00% | 32.63% | 20.38% | 27.73% | 24.06% | 27.01% | 25.00% | |
0.46 | 1.03 | 1.28 | 1.19 | 1.03 | -0.77 | 3.20 | 5.51 | 10.52 | 12.36 | 5.00 | 2.97 | 4.19 | |
EPS in Rs | 0.40 | 0.89 | 1.11 | 1.03 | 0.89 | -0.67 | 2.77 | 4.77 | 9.11 | 10.71 | 4.33 | 2.57 | 3.63 |
Dividend Payout % | 0.00% | 56.02% | 45.08% | 0.00% | 0.00% | 0.00% | 0.00% | 20.94% | 10.97% | 9.34% | 23.08% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 2% |
5 Years: | 6% |
3 Years: | -8% |
TTM: | 22% |
Compounded Profit Growth | |
---|---|
10 Years: | 10% |
5 Years: | -2% |
3 Years: | -34% |
TTM: | 29% |
Stock Price CAGR | |
---|---|
10 Years: | 17% |
5 Years: | 18% |
3 Years: | -24% |
1 Year: | -38% |
Return on Equity | |
---|---|
10 Years: | 13% |
5 Years: | 17% |
3 Years: | 13% |
Last Year: | 5% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 |
Reserves | 9.42 | 9.45 | 9.95 | 11.14 | 12.42 | 11.72 | 14.93 | 18.99 | 29.13 | 40.26 | 44.15 | 45.95 | 48.33 |
3.45 | 3.38 | 3.12 | 1.92 | 4.07 | 3.40 | 0.00 | 0.00 | 0.72 | 0.09 | 2.29 | 4.17 | 3.84 | |
8.74 | 9.77 | 9.95 | 7.76 | 11.75 | 10.19 | 11.70 | 10.60 | 13.25 | 4.89 | 7.81 | 12.12 | 9.95 | |
Total Liabilities | 33.15 | 34.14 | 34.56 | 32.36 | 39.78 | 36.85 | 38.17 | 41.13 | 54.64 | 56.78 | 65.79 | 73.78 | 73.66 |
16.56 | 15.22 | 14.26 | 13.86 | 15.06 | 14.60 | 14.07 | 14.11 | 15.90 | 13.83 | 19.91 | 22.90 | 21.58 | |
CWIP | 0.03 | 0.03 | 0.03 | 0.13 | 0.20 | 0.60 | 0.83 | 1.84 | 0.04 | 0.44 | 0.44 | 0.32 | 0.58 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.75 | 0.12 | 0.00 | 2.81 | 5.94 |
16.56 | 18.89 | 20.27 | 18.37 | 24.52 | 21.65 | 23.27 | 25.08 | 37.95 | 42.39 | 45.44 | 47.75 | 45.56 | |
Total Assets | 33.15 | 34.14 | 34.56 | 32.36 | 39.78 | 36.85 | 38.17 | 41.13 | 54.64 | 56.78 | 65.79 | 73.78 | 73.66 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.79 | 1.76 | 1.11 | 3.23 | 0.56 | 2.14 | 5.27 | 1.42 | 4.28 | 13.33 | -8.37 | 4.16 | |
0.00 | -0.07 | -0.28 | -0.82 | -2.62 | -1.11 | -0.50 | -1.82 | -1.18 | -8.80 | 3.20 | -6.63 | |
-0.84 | -0.60 | -1.52 | -2.41 | 1.76 | -1.01 | -3.65 | 1.15 | 0.31 | -1.86 | 0.93 | 0.33 | |
Net Cash Flow | -0.05 | 1.09 | -0.69 | 0.01 | -0.30 | 0.02 | 1.11 | 0.76 | 3.42 | 2.66 | -4.24 | -2.13 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 70.75 | 76.63 | 99.16 | 66.05 | 79.76 | 67.97 | 66.74 | 39.92 | 48.92 | 39.51 | 77.68 | 88.69 |
Inventory Days | 105.52 | 81.52 | 133.71 | 159.21 | 397.20 | 211.58 | 180.17 | 232.12 | 236.12 | 175.79 | 646.44 | 340.53 |
Days Payable | 69.49 | 68.68 | 116.18 | 108.07 | 262.26 | 127.21 | 138.98 | 114.32 | 120.62 | 17.35 | 137.50 | 126.54 |
Cash Conversion Cycle | 106.78 | 89.46 | 116.69 | 117.19 | 214.70 | 152.35 | 107.93 | 157.71 | 164.41 | 197.94 | 586.62 | 302.67 |
Working Capital Days | 94.02 | 83.15 | 100.80 | 91.94 | 128.09 | 114.27 | 93.19 | 81.92 | 102.61 | 143.09 | 213.91 | 227.98 |
ROCE % | 5.70% | 7.30% | 3.96% | 8.74% | 6.84% | 2.23% | 20.21% | 30.63% | 41.32% | 34.91% | 12.65% | 7.26% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
4 Apr - Submission of certificate under Regulation 74(5) of the SEBI [Depositories and Participants] Regulations, 2018 for the quarter ended March 31, 2025.
-
Closure of Trading Window
18 Mar - Closure of trading window for insiders.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
25 Jan - Results for the quarter ended December 31, 2024 published in Newspaper on January 25, 2025.
-
Integrated Filing (Financial)
24 Jan - Unaudited financial results for Q3 and 9 months ended December 31, 2024.
- Unaudited Financial Results For The Quarter And 9Months Ended December 31, 2024. 24 Jan
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
RSL is an integrated Product Development Company focusing on Pyridine and its derivatives. It also has expertise in organic
chemistry and expertise in catalysis.